




RealRate

PHARMACEUTICAL 2013

Cadence Pharmaceuticals INC
Rank 137 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cadence Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cadence Pharmaceuticals INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 31% points. The greatest weakness of Cadence Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 171%, being 49% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	76,516
Cost of Goods Sold	0
Intangible Assets	12,090
Liabilities, Current	20,999
Liabilities, Non-Current	28,869
Other Assets	7,106
Other Compr. Net Income	-2.0
Other Expenses	33,496
Other Liabilities	0
Other Net Income	-4,299
Other Revenues	50,184
Property and Equipment	1,967
Research and Development	6,519
Selling, General and Administrative Expense	86,843

Output Variable	Value in 1000 USD
Assets	97,679
Liabilities	49,868
Expenses	126,858
Revenues	50,184
Stockholders Equity	47,811
Net Income	-80,973
Comprehensive Net Income	-80,974
BaseVar	164,445
ECR before LimitedLiability	32%
Economic Capital Ratio	171%